HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jolles, P. R. Articles by Alavi, P. R. Search for Related Content PubMed PubMed Citation Articles by Jolles, P. R. Articles by Alavi, P. R.

PET, CT, and MRI in the Evaluation of Neuropshychiatric Disorder: Current Applications

Paul R. Jolles^*, Peter R. Chapman and Peter R. Alavi

Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Correspondence: For reprints contact: Abass Alavi, MD, Div. of Nuclear Medicine, Dept. of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.

ABSTRACT

Positron emission tomography (PET) is emerging as a very useful clinical tool and is adding a great deal to our understanding of the pathophysiology of central nervous system (CNS) disorders. Although computed tomography (CT) and magnetic resonance imaging (MRI) have had a dramatic impact on patient management, there is often an important associated function abnormality which is best assessed by PET. In normal aging and in dementia, the CT and MRI brain changes of atrophy and white matter abnormalities are frequently nonspecific. PET has been more diagnostic, showing characteristic regional metabolic abnormalities. Evaluation of brain tumors such as astrocytomas with PET has demonstrated better correlation with histologic grade compared to CT. Unlike CT or MRI, PET can help to distinguish radiation necrosis from recurrent tumor, and can differentiate the extent of metabolically active tumor from surrounding edema. PET is useful in evaluating stroke patients, providing better prognostic information and demonstrating abnormalities sooner than CT.In epilepsy, PET appears to be superior to MRI in localizing seizure foci in patients with partial seizures. In head trauma patients, metabolic patterns are being described which will likely have an effect on patient management. The use of PET in schizophrenia has yielded very interesting results, with common patterns of metabolic abnormalities being demonstrated. CT and MRI in these patients have not been very useful. PET has also shown promise in movement disorders such as Huntington's disease. It is now clear that PET is already clinically useful and can provide valuable information unobtainable by CT and MRI. As new radioligands are developed, PET is certain to assume an even more important role in the future.

FOOTNOTES

^* Present address: Department of Radiology, University of Arkansas for Medical Sciences, 4301 West Markham St. Little Rock, Arkansas 72205.

Present address: Nuclear Medicine & Ultrasound Associates, P.O.Box 6, Westmead. NSW 2145, Australia.

This article has been cited by other articles:

				A. Qureshy, R. Kawashima, M. B. Imran, M. Sugiura, R. Goto, K. Okada, K. Inoue, M. Itoh, T. Schormann, K. Zilles, et al. Functional Mapping of Human Brain in Olfactory Processing: A PET Study J Neurophysiol, September 1, 2000; 84(3): 1656 - 1666. [Abstract] [Full Text] [PDF]

				P. K. Shear, E. V. Sullivan, D. H. Mathalon, K. O. Lim, L. F. Davis, J. A. Yesavage, J. R. Tinklenberg, and A. Pfefferbaum Longitudinal Volumetric Computed Tomographic Analysis of Regional Brain Changes in Normal Aging and Alzheimer's Disease Arch Neurol, April 1, 1995; 52(4): 392 - 402. [Abstract] [PDF]